Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-α-tocopheryl poly(ethylene glycol 1000) succinate

Journal of Pharmacology and Experimental Therapeutics

Volumn 303, Issue 1, 2002, Pages 308-313

  Wacher, Vincent J ^a   Silverman, Jeffrey A ^b   Wong, Susan ^a   Tran Tau, Paulina ^a   Chan, Amy O ^a,b   Chai, Anne ^a,b   Yu, Xiang Qing ^a   O'Mahony, Daniel ^a   Ramtoola, Zeibun ^a  

^a AvMax Inc   (United States)

^b ELAN PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A; GLYCOPROTEIN P; KETOCONAZOLE; PROTEIN INHIBITOR; RAPAMYCIN; TOCOFERSOLAN;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; IC 50; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ADMINISTRATION, ORAL; ANIMALS; CELL LINE; HUMANS; INTESTINAL ABSORPTION; KETOCONAZOLE; KINETICS; MALE; METABOLIC CLEARANCE RATE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TUMOR CELLS, CULTURED; VITAMIN E;

EID: 0036786435     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.036541     Document Type: Article

References (24)

1. Arceci RJ, Stieglitz K, and Bierer BE (1992) Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 15:1528-1536.
2. Benet LZ (2000) The biochemical barriers to GI drug delivery. Presentation to the British Pharmaceutical Conference, Birmingham, United Kingdom. Pharm J 265:459.
3. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein using the principles of protein-dye binding. Anal Biochem 72:248-254.
4. Chan AO, Chai A, Waddell DA, and Silverman JA (2001) Characterization of Multidrug Resistance Associated Proteins (MRPs) in intestinal cells using a novel fluorescent substrate. Proc Am Assoc Cancer Res 42:951.
5. Chaudhary PM, Metchner EB, and Roninson IB (1992) Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739.
6. Crowe A and Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res (NY) 15:1666-1672.
7. Dias VC and Yatscoff RW (1994) Investigation of rapamycin transport and uptake across absorptive human intestinal cell monolayers. Clin Biochem 27:31-36.
8. Dias VC and Yatscoff RW (1996) An in vitro method for predicting in vivo oral bioavailability of novel immunosuppressive drugs. Clin Biochem 29:43-49.
9. Dintaman JM and Silverman JA (1999) Inhibition of P-glycoprotein by d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res (NY) 16:1550-1556.
10. Egudina SV, Stromskaya TP, Frolova EA, and Stravrovskaya AA (1993) Early steps of the P-glycoprotein in cell cultures studied with vital fluorochrome. FEBS Lett 329:63-66.
11. Evers R, Kool M, van Deemter L, Janssen H, Calafat J, Oomen LCJM, Paulusma CC, Oude E, Ronald PJ, Baas F, et al. (1998) Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2). J Clin Investig 101:1310-1319.
12. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
13. Hirohashi T, Suzuki H, Chu X-Y, Tamai I, Tsuji A, and Sugiyama Y (2000) Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 292:265-270.
14. Kaplan B, Meier-Kriesche H-U, Napoli KL, and Kahan BD (1998) The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. Clin Pharmacol Ther 63:48-53.
15. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing K-F, and Christians U (1998) Metabolism and transport of the immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285:1104-1112.
16. Maleki S, Graves S, Becker S, Horwatt R, Hicks D, Stroshane RM, and Kincaid H (2000) Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography. Clin Ther 22 (Suppl B):B25-B27.
17. Napoli KL, Wang ME, Stepkowski SM, and Kahan BD (1998) Relative tissue distributions of cyclosporine and sirolimus after concomitant peroral administration to the rat: evidence for pharmacokinetic interactions. Ther Drug Monit 20:123-133.
18. Stepkowski SM, Napoli KL, Wang M-E, Qu X, Chou T-C, and Kahan BD (1996) Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 62:986-994.
19. Streit F, Christians U, Schiebel H-M, Meyer A, and Sewing K-F (1996a) Structural identification of three metabolites and a degradation product of the macrolide immunosuppressant sirolimus (rapamycin) by electrospray-MS/MS after incubation with human liver microsomes. Drug Metab Dispos 24:1272-1278.
20. Streit F, Christians U, Schiebel H-M, Napoli KL, Ernst L, Linck A, Kahan BD, and Sewing K-F (1996b) Sensitive and specific quantification of sirolimus (rapamycin) and its metabolites in blood of kidney graft recipients by HPLC/electrospray-mass spectrometry. Clin Chem 42:1417-1425.
21. Wacher VJ, Silverman JA, Zhang Y, and Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 87:1322-1330.
22. Wacher VJ, Wong S, and Wong HT (2002) Peppermint oil enhances cyclosporine oral bioavailability in rats. Comparison to d-α-tocopheryl polyethylene glycol 1000 succinate (TPGS) and ketoconazole. J Pharm Sci 91:77-90.
23. Wu SH-W and Hopkins WK (1999) Characteristics of d-α-tocopheryl PEG 1000 succinate for applications as an absorption enhancer in drug delivery systems. Pharm Technol 23:52-60.
24. Yu L, Bridgers A, Polli J, Vickers A, Long S, Roy A, Winnike R, and Coffin M (1999) Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm Res (NY) 16:1812-1817.